Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a clinical study titled ‘A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer.’ The study aims to assess the efficacy of ABP 234 compared to the widely used pembrolizumab in treating advanced non-squamous non-small cell lung cancer. This research holds significant potential for enhancing treatment options for this severe condition.
The study is testing ABP 234, an experimental drug, against pembrolizumab, a well-established treatment. Both are administered intravenously and are intended to improve patient outcomes in lung cancer treatment.
This is a Phase 3 interventional study with a randomized, parallel assignment. It employs a double-blind approach, meaning neither participants nor investigators know which treatment is being administered, to ensure unbiased results. The primary goal is treatment efficacy.
The study began on September 9, 2024, with primary completion expected soon. The last update was on August 6, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and anticipating results.
Amgen’s study could influence its stock performance positively if ABP 234 shows favorable results, potentially enhancing its market position against competitors in the oncology sector. Investors should watch for updates as they could impact market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.